PTC518 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
8	Huntington disease	2

8. Huntington disease

---

Clinical trials : 242 /  Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2021-003852-18-DE (EUCTR)	06/05/2022	18/02/2022	A Phase 2A study of PTC518 in patients with Huntington's Disease	A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PTC518 IN SUBJECTS WITH HUNTINGTON'S DISEASE - PIVOT-HD	Huntington’s disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: PTC518 tablet 5 mg Product Code: PTC518 INN or Proposed INN: Not available Other descriptive name: PTC518 Product Name: PTC518 tablet 20 mg Product Code: PTC518 INN or Proposed INN: Not available Other descriptive name: PTC518	PTC Therapeutics, INC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	162	Phase 2	France;United States;Australia;Netherlands;Germany;United Kingdom
2	NCT05358717 (ClinicalTrials.gov)	April 25, 2022	27/4/2022	A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)	A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease	Huntington Disease	Drug: PTC518;Drug: Placebo	PTC Therapeutics	NULL	Recruiting	25 Years	N/A	All	162	Phase 2	United States;Australia;France;Germany;Netherlands;United Kingdom